Obesity Ends Oncology’s Long Reign as Top Contributor to Biopharma Pipeline Value

Why It Matters

The re‑ranking signals a strategic pivot for drug developers toward obesity treatments, promising new revenue streams but also heightening exposure to a narrow set of high‑stakes programs. Investors and R&D leaders must reassess portfolios as the market’s focus moves from cancer to weight‑loss therapies.

Key Takeaways

• Obesity now accounts for 25% of 2025 pipeline value, overtaking oncology.
• Eli Lilly and Novo Nordisk hold 96% of obesity asset value.
• GLP‑1/GIP drugs lift average peak‑sale forecasts to $598 M per asset.
• Development cost per asset rose to $2.67 B in 2025.
• Mega‑blockbusters (> $10 B) are 9% of assets, 70% of value.

Pulse Analysis

The surge of obesity‑focused therapeutics reflects broader societal trends: rising prevalence of metabolic disease and the commercial success of GLP‑1 agents have turned weight‑loss drugs into blockbuster candidates. Unlike oncology, where pipelines are diversified across dozens of indications, obesity now concentrates value in a handful of molecules, primarily from Eli Lilly and Novo Nordisk. This concentration amplifies the financial upside of successful launches but also magnifies the impact of any clinical setback, prompting investors to scrutinize trial data more closely than ever.

Financially, the Deloitte report highlights a sharp uptick in both projected peak sales and internal rate of return for late‑stage assets, driven largely by GLP‑1/GIP combinations. Average peak‑sale forecasts jumped from $510 million to $598 million per asset, while the IRR rose to 7% for the full pipeline. However, when GLP‑1 drugs are excluded, those metrics dip, underscoring how heavily the sector’s economics now rely on a single drug class. Development costs have also escalated, reaching $2.67 billion per asset, a reflection of higher clinical trial complexity and the premium placed on novel mechanisms.

Strategically, major players are racing to secure a foothold in the obesity market. Eli Lilly’s recent approval of its oral pill, Foundayo, positions it directly against Novo Nordisk’s established GLP‑1 portfolio, while Pfizer and Roche are accelerating acquisitions and internal programs to join the top tier. As the pipeline becomes increasingly dominated by mega‑blockbusters, companies must balance aggressive growth ambitions with the inherent risk of value erosion should a lead candidate falter. The next few years will likely see intensified M&A activity, partnership deals, and a sharpening of R&D focus on metabolic health as the new engine of biopharma growth.